Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors

Non-small cell lung cancer (NSCLC) driven by activating mutations in epidermal growth factor receptor (EGFR) constitutes up to 10% of NSCLC cases. According to the NCCN recommendations, all patients (with the exception of smoking patients with squamous cell lung cancer) should be screened for the pr...

Full description

Bibliographic Details

Published in:	Contemporary Oncology
Main Authors:	Marcin Skrzypski, Amelia Szymanowska-Narloch, Rafał Dziadziuszko
Format:	Article
Language:	English
Published:	Termedia Publishing House 2017-09-01
Subjects:	lung cancer chemotherapy TKI inhibitors osimertinib
Online Access:	https://www.termedia.pl/Osimertinib-effective-treatment-of-NSCLC-with-activating-EGFR-mutations-after-progression-on-EGFR-tyrosine-kinase-inhibitors,3,30597,1,1.html